Vor Bio is trying to help AML patients who receive a stem cell transplant to be more amenable to follow-on therapies - they just had key PoC data

blonca9
Oct 2, 2024
1 min read

President and CEO Robert Ang describes how Vor knocks out CD33 in transplant cells before they are administered so that patients can tolerate follow-on treatments like Mylotarg and CAR-T easier and earlier. He describes clinical data the company announced last month.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Vor Bio is trying to help AML patients who receive a stem cell transplant to be more amenable to follow-on therapies - they just had key PoC data

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight